THE EXPRESSION OF CD26 AND CD40 LIGAND IS MUTUALLY EXCLUSIVE IN HUMAN T-CELL NON-HODGKINS-LYMPHOMAS LEUKEMIAS
THE EXPRESSION OF CD26 AND CD40 LIGAND IS MUTUALLY EXCLUSIVE IN HUMAN T-CELL NON-HODGKINS-LYMPHOMAS LEUKEMIAS
复制标题
DOI：
10.1182/blood.v86.12.4617.bloodjournal86124617
复制
发表时间：
1995-12-15
期刊：
影响因子：
20.3
通讯作者：
PINTO, A
中科院分区：
文献类型：
--
作者：
CARBONE, A;GLOGHINI, A;PINTO, A
CD26和CD40配体（CD40L）是人活化T淋巴细胞的表面分子，在淋巴生成的调控中起关键作用。这两种分子在人类t细胞非霍奇金淋巴瘤(NHL)/白血病的有限部分中表达；然而。对于它们在这些疾病中的功能和/或临床意义知之甚少。本研究比较了CD40L与CD26分子的表达模式。通过免疫组织化学、流式细胞术和RNA研究，对67例人类t细胞NHL/白血病和一组白血病/淋巴瘤t细胞系进行了评估。CD26（+）和CD40L（+）样本的总体频率相当相似（25/67[37%]和18/67[27%]）。然而，大多数表达cd26的病例集中在淋巴母细胞淋巴瘤(LBL)/ t -急性淋巴母细胞白血病（ALL; 12/23）和CD30（+）间变性大细胞淋巴瘤（ALC）（5/8），而CD40L（+）淋巴瘤包括很大一部分蕈样真菌病（11/21[52%]）。CD26和CD40L共表达仅在2例蕈样真菌病和1例小淋巴细胞淋巴瘤中发现。因此，在几乎所有的t细胞淋巴瘤/白血病中，这两种抗原的表达是互斥的。因此，淋巴瘤细胞系表达任一分子或CD26和CD40L的相对量成反比。相比之下，来自非肿瘤性T细胞扩增患者和体外活化的CD3（+）或CD4（+）正常T细胞的反应性T淋巴细胞被发现共表达CD40L和CD26。一项多变量分析结果显示，与CD26（-）肿瘤患者相比，t细胞LBL/ALL患者中CD26的表达与更差的生存结果相关（P小于或等于0.0001）。根据我们的研究结果，可以得出结论：(1)与活化或反应性正常T细胞相反，CD26和CD40L的表达在人类T细胞淋巴瘤/白血病中是相互排斥的；(2) CD26的表达仅限于侵袭性病理实体。如t细胞LBL/ALL和t细胞CD30(+) ALC淋巴瘤，而CD40L表达于进展缓慢的疾病，如蕈样真菌病；(3)在t细胞LBL/ALL肿瘤组中，CD26可以识别预后不良患者的亚群。(C) 1995年由美国血液病学会出版。
CD26 and CD40 ligand (CD40L) are surface molecules on human activated T lymphocytes that play a critical role in the regulation of lymphopoiesis. Both molecules are expressed on a restricted fraction of human T-cell non-Hodgkin's lymphomas (NHL)/leukemias; however. little is known about their functional and/or clinical significance in these disorders. In this study, the pattern of expression of CD40L was compared with that of the CD26 molecule. A series of 67 human T-cell NHL/leukemias and a panel of leukemia/lymphoma T-cell lines were evaluated by immunohistochemistry, flow cytometry, and RNA studies. The overall frequency of CD26(+) and CD40L(+) samples was rather similar (25/67 [37%] v 18/67 [27%]). However, the majority of CD26-expressing cases clustered in the lymphoblastic lymphomas (LBL)/T-acute lymphoblastic leukemias (ALL; 12/23) and CD30(+) anaplastic large-cell (ALC) lymphomas (5/8), whereas CD40L(+) lymphomas included a large fraction of mycosis fungoides (11/21 [52%]). CD26 and CD40L coexpression was found only in 2 mycosis fungoides cases and 1 small lymphocytic lymphoma. Thus, the expression of the two antigens was mutually exclusive in almost all T-cell lymphomas/leukemias. Accordingly, lymphoma cell lines expressed either one of the molecules or the relative amounts of CD26 and CD40L were inversely proportional. In contrast, reactive T lymphocytes from patients with non-neoplastic T-cell expansions and in vitro activated CD3(+) or CD4(+) normal T cells were found to coexpress CD40L and CD26. Results of a multivariate analysis showed that the expression of CD26 in T-cell LBL/ALL patients was associated to a worse outcome in terms of survival, as compared with patients with CD26(-) tumors (P less than or equal to.0001). Based on our results, it can be concluded that, (1) as opposed to activated or reactive normal T cells, the expression of CD26 and of CD40L is mutually exclusive in human T-cell lymphomas/leukemias; (2) expression of CD26 is restricted to aggressive pathologic entities. such as T-cell LBL/ALL and T-cell CD30(+) ALC lymphomas, whereas CD40L is expressed on slow progressing diseases such as mycosis fungoides; and (3) within the T-cell LBL/ALL group of tumors, CD26 may identify a subset of poor prognosis patients. (C) 1995 by The American Society of Hematology.